TW202204605A - 增殖細胞之生產方法、細胞生產物之生產方法、間質幹細胞群及其生產方法、幹細胞之培養上清液及其生產方法、以及治療劑 - Google Patents
增殖細胞之生產方法、細胞生產物之生產方法、間質幹細胞群及其生產方法、幹細胞之培養上清液及其生產方法、以及治療劑 Download PDFInfo
- Publication number
- TW202204605A TW202204605A TW110111636A TW110111636A TW202204605A TW 202204605 A TW202204605 A TW 202204605A TW 110111636 A TW110111636 A TW 110111636A TW 110111636 A TW110111636 A TW 110111636A TW 202204605 A TW202204605 A TW 202204605A
- Authority
- TW
- Taiwan
- Prior art keywords
- cells
- culture
- medium
- aforementioned
- mesenchymal stem
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 198
- 230000002062 proliferating effect Effects 0.000 title claims abstract description 126
- 210000004027 cell Anatomy 0.000 title claims description 674
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims description 310
- 239000012228 culture supernatant Substances 0.000 title claims description 272
- 210000000130 stem cell Anatomy 0.000 title claims description 118
- 239000000047 product Substances 0.000 title claims description 70
- 239000003814 drug Substances 0.000 title claims description 57
- 229940124597 therapeutic agent Drugs 0.000 title claims description 53
- 239000012634 fragment Substances 0.000 claims abstract description 292
- 238000000034 method Methods 0.000 claims abstract description 247
- 230000035755 proliferation Effects 0.000 claims abstract description 119
- 238000012258 culturing Methods 0.000 claims abstract description 97
- 230000027455 binding Effects 0.000 claims abstract description 70
- 102000006495 integrins Human genes 0.000 claims abstract description 57
- 108010044426 integrins Proteins 0.000 claims abstract description 57
- 239000000758 substrate Substances 0.000 claims abstract description 21
- 239000002609 medium Substances 0.000 claims description 220
- 239000001963 growth medium Substances 0.000 claims description 103
- 239000013587 production medium Substances 0.000 claims description 97
- 210000003954 umbilical cord Anatomy 0.000 claims description 84
- 102000004127 Cytokines Human genes 0.000 claims description 78
- 108090000695 Cytokines Proteins 0.000 claims description 78
- 238000011084 recovery Methods 0.000 claims description 76
- 238000004113 cell culture Methods 0.000 claims description 49
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 34
- 239000006228 supernatant Substances 0.000 claims description 25
- 102100037241 Endoglin Human genes 0.000 claims description 22
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 22
- 108010067306 Fibronectins Proteins 0.000 claims description 18
- 102000004877 Insulin Human genes 0.000 claims description 17
- 108090001061 Insulin Proteins 0.000 claims description 17
- 229940125396 insulin Drugs 0.000 claims description 17
- 108090000978 Interleukin-4 Proteins 0.000 claims description 16
- 102100025222 CD63 antigen Human genes 0.000 claims description 15
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 15
- 102000003814 Interleukin-10 Human genes 0.000 claims description 15
- 108090000174 Interleukin-10 Proteins 0.000 claims description 15
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 14
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 14
- 102000037865 fusion proteins Human genes 0.000 claims description 14
- 108020001507 fusion proteins Proteins 0.000 claims description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 12
- 230000001464 adherent effect Effects 0.000 claims description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 8
- 238000004115 adherent culture Methods 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 7
- 102000004338 Transferrin Human genes 0.000 claims description 7
- 108090000901 Transferrin Proteins 0.000 claims description 7
- 239000012581 transferrin Substances 0.000 claims description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010085895 Laminin Proteins 0.000 description 258
- 238000010899 nucleation Methods 0.000 description 58
- 108090000623 proteins and genes Proteins 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 39
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 35
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 30
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 30
- 239000003102 growth factor Substances 0.000 description 30
- 210000003141 lower extremity Anatomy 0.000 description 26
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 22
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 22
- 210000002744 extracellular matrix Anatomy 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- 108010038862 laminin 10 Proteins 0.000 description 19
- 230000001225 therapeutic effect Effects 0.000 description 19
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 18
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 18
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 18
- 102100037362 Fibronectin Human genes 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 239000006285 cell suspension Substances 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 208000028867 ischemia Diseases 0.000 description 16
- 102000004388 Interleukin-4 Human genes 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 15
- 229920002971 Heparan sulfate Polymers 0.000 description 14
- 235000010724 Wisteria floribunda Nutrition 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- 238000001000 micrograph Methods 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 13
- 102000000704 Interleukin-7 Human genes 0.000 description 13
- 108010002586 Interleukin-7 Proteins 0.000 description 13
- 229940100994 interleukin-7 Drugs 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 210000004700 fetal blood Anatomy 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000000644 propagated effect Effects 0.000 description 9
- 229920001342 Bakelite® Polymers 0.000 description 8
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 8
- -1 CD31 Proteins 0.000 description 8
- 208000009329 Graft vs Host Disease Diseases 0.000 description 8
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 8
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 8
- 239000003797 essential amino acid Substances 0.000 description 8
- 235000020776 essential amino acid Nutrition 0.000 description 8
- 208000024908 graft versus host disease Diseases 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 7
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 7
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 7
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 208000018262 Peripheral vascular disease Diseases 0.000 description 7
- 206010058571 Spinal cord infarction Diseases 0.000 description 7
- 238000012832 cell culture technique Methods 0.000 description 7
- 206010008118 cerebral infarction Diseases 0.000 description 7
- 208000026106 cerebrovascular disease Diseases 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 210000001671 embryonic stem cell Anatomy 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 7
- 108010028309 kalinin Proteins 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 102100022464 5'-nucleotidase Human genes 0.000 description 6
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 6
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 6
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 6
- 102000003816 Interleukin-13 Human genes 0.000 description 6
- 108090000176 Interleukin-13 Proteins 0.000 description 6
- 102000003812 Interleukin-15 Human genes 0.000 description 6
- 108090000172 Interleukin-15 Proteins 0.000 description 6
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 208000023589 ischemic disease Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000002826 placenta Anatomy 0.000 description 6
- 102000000013 Chemokine CCL3 Human genes 0.000 description 5
- 102100023688 Eotaxin Human genes 0.000 description 5
- 101710139422 Eotaxin Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 108010002335 Interleukin-9 Proteins 0.000 description 5
- 102000000585 Interleukin-9 Human genes 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 239000002458 cell surface marker Substances 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000001665 muscle stem cell Anatomy 0.000 description 5
- 210000001178 neural stem cell Anatomy 0.000 description 5
- 210000001778 pluripotent stem cell Anatomy 0.000 description 5
- 206010003805 Autism Diseases 0.000 description 4
- 208000020706 Autistic disease Diseases 0.000 description 4
- 208000027932 Collagen disease Diseases 0.000 description 4
- 206010050685 Cytokine storm Diseases 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000014429 Insulin-like growth factor Human genes 0.000 description 4
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 4
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 206010052015 cytokine release syndrome Diseases 0.000 description 4
- 210000001808 exosome Anatomy 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 230000003959 neuroinflammation Effects 0.000 description 4
- 230000003169 placental effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 208000001076 sarcopenia Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000001988 somatic stem cell Anatomy 0.000 description 4
- 238000009331 sowing Methods 0.000 description 4
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 201000002818 limb ischemia Diseases 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- 102100031092 C-C motif chemokine 3 Human genes 0.000 description 2
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 2
- 108010055124 Chemokine CCL7 Proteins 0.000 description 2
- 102000010970 Connexin Human genes 0.000 description 2
- 108050001175 Connexin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000004125 Interleukin-1alpha Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000008472 epithelial growth Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000002993 trophoblast Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 240000003023 Cosmos bipinnatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 230000028550 monocyte chemotaxis Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/12—Hepatocyte growth factor [HGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/231—Interleukin-10 (IL-10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020063408 | 2020-03-31 | ||
| JP2020-063408 | 2020-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202204605A true TW202204605A (zh) | 2022-02-01 |
Family
ID=77930052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110111636A TW202204605A (zh) | 2020-03-31 | 2021-03-30 | 增殖細胞之生產方法、細胞生產物之生產方法、間質幹細胞群及其生產方法、幹細胞之培養上清液及其生產方法、以及治療劑 |
| TW111147409A TW202311526A (zh) | 2020-03-31 | 2021-03-30 | 增殖細胞之生產方法、細胞生產物之生產方法、間質幹細胞群及其生產方法、幹細胞之培養上清液及其生產方法、以及治療劑 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111147409A TW202311526A (zh) | 2020-03-31 | 2021-03-30 | 增殖細胞之生產方法、細胞生產物之生產方法、間質幹細胞群及其生產方法、幹細胞之培養上清液及其生產方法、以及治療劑 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230172992A1 (https=) |
| EP (2) | EP4130240A4 (https=) |
| JP (3) | JPWO2021200744A1 (https=) |
| CN (2) | CN115362252A (https=) |
| AU (2) | AU2021247879B2 (https=) |
| CA (2) | CA3177567A1 (https=) |
| TW (2) | TW202204605A (https=) |
| WO (1) | WO2021200744A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2021200744A1 (https=) * | 2020-03-31 | 2021-10-07 | ||
| EP4324914B1 (en) * | 2021-06-11 | 2026-03-18 | Fullstem Co., Ltd. | Exosome production promoting agent and exosome production promoting method |
| JP7763475B2 (ja) * | 2021-12-24 | 2025-11-04 | 株式会社日本バイオセラピー研究所 | 培養上清を生産する方法 |
| WO2024019080A1 (ja) * | 2022-07-19 | 2024-01-25 | 国立大学法人 長崎大学 | 血管内皮増殖因子を高発現する臍帯由来間葉系細胞の製造方法、および肺疾患治療用医薬組成物 |
| JP7851648B2 (ja) * | 2022-12-23 | 2026-04-27 | Ｃｅｌｌ Ｅｘｏｓｏｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 | 間葉系幹細胞又はその培養上清の利用 |
| WO2025151805A1 (en) * | 2024-01-10 | 2025-07-17 | Biotech Therapeutics, LLC | Mesenchymal stromal cell-derived extracellular vesicle-exosomes |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378612A (en) * | 1990-05-11 | 1995-01-03 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Culture medium for production of recombinant protein |
| JPH05207875A (ja) * | 1992-01-28 | 1993-08-20 | Mitsui Toatsu Chem Inc | 無血清培地 |
| AU680909B2 (en) * | 1994-04-06 | 1997-08-14 | Immunex Corporation | Interleukin-15 |
| JPH10179147A (ja) * | 1996-12-27 | 1998-07-07 | Ishikawajima Harima Heavy Ind Co Ltd | 植物細胞培養方法および二次代謝物高生産性植物細胞 |
| EP1930413B1 (en) * | 2005-08-23 | 2011-01-12 | Oriental Yeast Co., Ltd. | Technique for culture of mesenchymal stem cell utilizing laminin-5 |
| AU2007294731B2 (en) * | 2006-09-13 | 2014-04-17 | Abbvie Inc. | Cell culture improvements |
| WO2010040262A1 (zh) * | 2008-10-10 | 2010-04-15 | 深圳市嘉天源生物科技有限公司 | 分离动物胚胎间质性干细胞并提取其分泌物的方法 |
| WO2012137970A1 (ja) | 2011-04-08 | 2012-10-11 | 国立大学法人大阪大学 | 改変ラミニンおよびその利用 |
| WO2012145682A1 (en) * | 2011-04-21 | 2012-10-26 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| CN104884468B (zh) | 2012-12-28 | 2018-08-31 | 国立大学法人大阪大学 | 附加有胶原结合性分子的改造层粘连蛋白及其利用 |
| WO2014199754A1 (ja) * | 2013-06-12 | 2014-12-18 | 国立大学法人大阪大学 | ラミニンフラグメントが乾燥状態でコーティングされている細胞培養器具 |
| CN106559994A (zh) * | 2014-07-16 | 2017-04-05 | 国立大学法人大阪大学 | 层粘连蛋白片段的细胞培养基质活性增强方法 |
| CN104651305A (zh) * | 2015-02-13 | 2015-05-27 | 沈阳澔源生物科技有限公司 | 一种利用脐带间充质干细胞获取生物活性蛋白的方法 |
| JP6849957B2 (ja) * | 2015-11-10 | 2021-03-31 | 国立大学法人京都大学 | ラミニンフラグメント含有培地を用いる細胞培養方法 |
| RU2742828C2 (ru) * | 2016-03-09 | 2021-02-11 | Авита Интернэшнл Лтд. | Применение стволовых клеток, экспрессирующих мезенхимальные и нейрональные маркеры, и их композиций для лечения неврологических заболеваний (варианты) |
| AU2018228352B2 (en) * | 2017-02-28 | 2024-08-01 | Centre Hospitalier Régional Universitaire De Nancy | Mesenchymal stem cells obtained from Wharton's jelly for the treatment of sepsis |
| JP6469287B1 (ja) * | 2018-06-22 | 2019-02-13 | 株式会社 バイオミメティクスシンパシーズ | 中空糸細胞培養装置，細胞培養方法，培養上清の製造方法 |
| JPWO2021200744A1 (https=) * | 2020-03-31 | 2021-10-07 |
-
2021
- 2021-03-26 JP JP2022512159A patent/JPWO2021200744A1/ja active Pending
- 2021-03-26 EP EP21779739.8A patent/EP4130240A4/en active Pending
- 2021-03-26 CN CN202180024893.1A patent/CN115362252A/zh active Pending
- 2021-03-26 EP EP22207135.9A patent/EP4155389A3/en active Pending
- 2021-03-26 US US17/995,095 patent/US20230172992A1/en active Pending
- 2021-03-26 AU AU2021247879A patent/AU2021247879B2/en active Active
- 2021-03-26 WO PCT/JP2021/013099 patent/WO2021200744A1/ja not_active Ceased
- 2021-03-26 CN CN202310081275.1A patent/CN116179480A/zh not_active Withdrawn
- 2021-03-26 CA CA3177567A patent/CA3177567A1/en active Pending
- 2021-03-26 CA CA3173721A patent/CA3173721A1/en active Pending
- 2021-03-30 TW TW110111636A patent/TW202204605A/zh unknown
- 2021-03-30 TW TW111147409A patent/TW202311526A/zh unknown
-
2022
- 2022-10-04 JP JP2022160399A patent/JP2022181218A/ja active Pending
- 2022-10-25 AU AU2022259729A patent/AU2022259729B2/en active Active
-
2023
- 2023-12-06 JP JP2023206347A patent/JP2024015245A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021247879A1 (en) | 2022-11-03 |
| EP4155389A3 (en) | 2023-07-12 |
| JPWO2021200744A1 (https=) | 2021-10-07 |
| EP4130240A1 (en) | 2023-02-08 |
| CA3177567A1 (en) | 2021-10-07 |
| EP4130240A4 (en) | 2024-05-08 |
| EP4155389A2 (en) | 2023-03-29 |
| CN116179480A (zh) | 2023-05-30 |
| TW202311526A (zh) | 2023-03-16 |
| AU2022259729B2 (en) | 2025-05-01 |
| AU2022259729A1 (en) | 2022-12-01 |
| AU2021247879B2 (en) | 2025-04-24 |
| JP2024015245A (ja) | 2024-02-01 |
| US20230172992A1 (en) | 2023-06-08 |
| JP2022181218A (ja) | 2022-12-07 |
| WO2021200744A1 (ja) | 2021-10-07 |
| CN115362252A (zh) | 2022-11-18 |
| CA3173721A1 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202204605A (zh) | 增殖細胞之生產方法、細胞生產物之生產方法、間質幹細胞群及其生產方法、幹細胞之培養上清液及其生產方法、以及治療劑 | |
| Wei et al. | JNKi-and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia | |
| CA2867953C (en) | Regulating stem cells | |
| US20060110825A1 (en) | Process for the preparation of stem cells from human muscle tissue and adipose tissue, and stem cell obtainable by this process | |
| JP4085062B2 (ja) | 霊長類の胚性幹細胞から由来した内皮細胞 | |
| JPWO2017188403A1 (ja) | Ｃｄ２０１、ｃｄ４６、ｃｄ５６、ｃｄ１４７及びｃｄ１６５からなる群より選択される少なくとも１種の細胞表面マーカーを発現する間葉系幹細胞及びその調製方法、並びに上記間葉系幹細胞を含む医薬組成物及びその調製方法 | |
| CN110898078B (zh) | 一种间充质干细胞分泌因子的制备及应用 | |
| TW201512399A (zh) | Ｎｋ細胞的調製方法 | |
| CN108138137A (zh) | 增强的脐带来源的粘着干细胞、其制备方法及其用途 | |
| JP2023052609A (ja) | 細胞培養物の製造方法 | |
| WO2003050273A1 (en) | Human cell culture medium and culture method | |
| US20130259837A1 (en) | Compositions and Methods of Using Living and Non-Living Bioactive Devices with Components Derived From Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro | |
| JP7329265B2 (ja) | ヒト多能性成人幹細胞 | |
| US20240117301A1 (en) | Method for producing proliferating cells, method for producing cell product, mesenchymal stem cell population and method for producing same, culture supernatant of stem cells and method for producing same, and therapeutic agent | |
| HK40089499A (zh) | 增殖细胞和细胞生产物的生产法、间充质干细胞群和干细胞培养上清及其生产法、治疗剂 | |
| HK40084736A (en) | Method for producing proliferating cells, method for producing cell product, mesenchymal stem cell population and method for producing same, culture supernatant of stem cells and method for producing same, and therapeutic agent | |
| NZ793106A (en) | Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent | |
| JP2003235548A (ja) | ヒト細胞の培養用培地および培養方法 | |
| CN120958115A (zh) | 间充质干细胞增殖促进剂、间充质干细胞用培养基、间充质干细胞及培养上清液 | |
| KR20250142323A (ko) | 세포분화도의 조절 방법 | |
| KR102257950B9 (ko) | 혈관 내피세포 특성 유지 배지 및 이를 포함하는 배양 방법 | |
| IL193947A (en) | Cells cultured as cd31brigi: it, a method for stimuli to differentiate into a congenital / precursor cell population (pcp), use of the same drug preparation population, and implantation device that includes it | |
| HK1149942A (en) | Paracrine signals from mesenchymal feeder cells and regulating expansion and differentiation of hepatic progenitors using same |